COMMUNIQUÉS West-GlobeNewswire

TYME Announces Leadership Team Update
18/03/2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, announced a realignment in responsibilities among its [...]
Tabula Rasa HealthCare Chief Strategic Growth Officer to Present at Innovation Showcase
18/03/2019
“Advancing Value through the Science of Personalized Medication Management” MOORESTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) Chief Strategic Growth Officer, Brian Litten, [...]
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
18/03/2019
NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that [...]
Emerald Health Therapeutics Appoints Vice President, Communications and Stakeholder Relations
18/03/2019
Allan Rewak brings extensive experience with government, media, communications and public affairs VICTORIA, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “ [...]
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Paratek Pharmaceuticals Announces Management Change
18/03/2019
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
The Joint Corp. Acquires Clinic in Los Angeles County
18/03/2019
- Accelerating Expansion of Company-Owned or Managed Clinics, Represents the Third Added to the Portfolio in 2019 - SCOTTSDALE, Ariz., March 18, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national [...]
MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
18/03/2019
YAVNE, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, [...]
Tauriga Sciences, Inc. Receives Initial $54,000 Tauri-Gum Purchase Order from Major New York City Based Distributor
18/03/2019
NEW YORK, NY, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
Medovex Corporation Receives an Additional $1.25 Million Under Existing Securities Purchase Agreement
18/03/2019
Increases Maximum Offering Size from $6M to $8M ALPHARETTA, Ga., March 18, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”) today announced that on March 11, 2019, the Company [...]
Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
18/03/2019
WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine [...]
AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
18/03/2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]
Teligent, Inc. Announces Fourth Quarter and Year End 2018 Results
18/03/2019
BUENA, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended [...]
Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results
18/03/2019
RICHMOND HILL, Ontario, March 18, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates [...]
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
18/03/2019
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
18/03/2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into [...]
GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M
18/03/2019
CARLSBAD, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, [...]
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
18/03/2019
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period - Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in recurrent pericarditis [...]
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
18/03/2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has [...]

Pages